|
tofacitinib Clinical Trials
5 actively recruiting trials across 4 locations
▲ +1 trial since June 2026
Also known as: Jakvinus, Xeljanz
Pipeline
Phase 2: 2Phase 3: 2Phase 4: 1
Top Sponsors
- University of Nebraska1
- National Institute of Dental and Craniofacial Research (NIDCR)1
- NYU Langone Health1
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1
- Duke University1
Indications
- Arthritis5
- Rheumatoid Arthritis2
- Rheumatic Disease1
- Polyarticular Course Juvenile Idiopathic Arthritis (JIA)1
- Sjogren's Syndrome1
Other1 trial
San Francisco, California1 trial
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
University of California San Francisco Pediatric Rheumatology
Phase 3
Bethesda, Maryland1 trial
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
National Institutes of Health Clinical Center
Phase 2
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
New York, New York1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.